MU
Marshall Urist sold $1.7M of RPRX stock
Marshall Urist, EVP, Research & Investments of Royalty Pharma plc (RPRX), sold 25,000 shares of RPRX stock worth $1.7M, per an SEC Form 4 filed Nov 18, 2026.
The sale was pre-arranged (a 10b5-1 plan or an option exercise), not a fresh decision.
The trade happened on Nov 16, 2026, 2 days before it was made public.
RPRX has moved -1.2% since the trade date, from $68.53 to $67.72 (Nov 19, 2026 close).
- Traded
- Nov 16, 2026
- Disclosed
- Nov 18, 2026
- Filing delay
- 2 days
- Price since
- -1.2%
- Role
- EVP, Research & Investments
- Source
- SEC Form 4